Ikena Oncology, Inc.

No trades
See on Supercharts
Market capitalization
‪64.18 M‬USD
−1.62USD
‪−68.77 M‬USD
‪15.62 M‬USD
‪25.16 M‬
Beta (1Y)
0.87

About Ikena Oncology, Inc.

CEO
Mark Manfredi
Headquarters
Boston
Employees (FY)
80
Founded
2016
ISIN
US45175G1085
FIGI
BBG00XZY4TG9
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed, and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
Performance
Revenue to profit conversion
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Interactive Brokers
Stocks, Forex, Futures, Bonds
4.5Great

See all brokers